With this change, it’s now more important than ever to ensure the right Investigational Medicinal Product (IMP) reaches the right patient at the right time.
TORONTO (PRWEB) November 30, 2020
The current pandemic has had a significant impact on clinical development, calling for the implementation of decentralized trials. With this change, it’s now more important than ever to ensure the right Investigational Medicinal Product (IMP) reaches the right patient at the right time.
So how do sponsors go about implementing direct-to-patient models and how do they maintain the chain of custody for the life of an IMP? This insightful webinar will take participants through the what, why and how of performing various direct-to-patient models. Participants will gain knowledge of the important areas to consider before executing, such as:
- Additional data requirements needed
- What information needs to be held in the Interactive Response Technology (IRT)
- What steps can be taken to safeguard trials beyond the pandemic
Join expert speakers from Almac Clinical Technologies, Matt Lowrie, ASQ CQA, QA Manager, Quality Assurance; Abby Sener, Manager, Almac ONE, ACS Project Services; and Kat Williams, Manager, Clinical Project Services, in a live webinar on Tuesday, December 15, 2020 at 11am EST (4pm GMT/UK).
For more information, or to register for this event, visit Direct-to-Patient: Implementing Models for Continuous Treatment During the Pandemic And Beyond.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.